Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
There are a lot of reasons to be skeptical of the HHS effort to bring international reference prices into Medicare via the proposed GLOBE […]
On Tuesday July 28, the Arkansas State Board of Pharmacy suspended enforcement of a 2025 Arkansas law, Act 630, two months after a federal
Following court decision, Arkansas will not enforce Act 630 on drug distribution Read More »
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) will consider this week whether seven unapproved peptides should be added to the Section 503A Bulk Drug
FDA Advisory Committee to weigh whether to expand compounding of unapproved peptides Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
Researchers utilize health data to inform medical breakthroughs, but patients need to know their personal information stays confidential. The current patchwork of state laws
House hearing to examine bill balancing data privacy and R&D needs Read More »
The Administration’s Council of Economic Advisors (CEA) has released an analysis of savings expected from its “Most Favored Nation” deals with pharmaceutical manufacturers, but
Exaggerated MFN cost-saving estimates imperil U.S. innovation and investment Read More »
Ohio’s diverse biotech sector provides the state with employment for 65,000 and provides the world with medical breakthroughs. Of the first eight gene therapies
BIO on the American Road tours gene therapy hub in Ohio Read More »
As biotech celebrates its 50th year, we are locked in “the fight of our lives” to ensure patients get more of the medical innovations
At some point in our lives, many of us will find ourselves in a health fight we didn’t expect. A diagnosis. A test result.
Strong intellectual property protections sustain biotechnology innovation by enabling the investment needed to develop new medical breakthroughs. In comments submitted for the 2026 U.S.
BIO’s comments for USTR report highlight global threats to intellectual property Read More »
